In an effort to suppress B-Raf activity without stimulating cancer growth, second-generation Raf inhibitors including type II pan-Raf inhibitors and paradox-breakers were developed to hinder dimerization-driven transactivation. The gene discussed is RAF1; the disease is cancer.